PUBLISHER: The Business Research Company | PRODUCT CODE: 1951669
PUBLISHER: The Business Research Company | PRODUCT CODE: 1951669
Crohn's disease treatment refers to the medical interventions and therapies used to manage Crohn's disease, a chronic inflammatory condition affecting the gastrointestinal tract. The goals of treatment are to reduce intestinal inflammation, prevent symptom flare-ups, and maintain remission.
The main drug types used in Crohn's disease treatment include antibiotics, aminosalicylates, corticosteroids, immunomodulators, and others. Antibiotics are medications used to treat and prevent bacterial infections. These drugs are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used in applications including neuropathic pain, fibromyalgia, chronic back pain, arthritic pain, migraine, post-operative pain, cancer pain, and others.
Tariffs have influenced the Crohn's disease treatment market by increasing the cost of imported active pharmaceutical ingredients, biologics, and advanced manufacturing inputs, impacting overall drug pricing and supply stability. Immunomodulators, biologics, and specialty drugs are most affected, with Asia-Pacific and Europe experiencing notable pressure due to reliance on cross-border pharmaceutical supply chains. However, tariffs have also encouraged local manufacturing, regional sourcing, and domestic API production, supporting long-term supply resilience and reduced import dependency.
The crohn's disease treatment market research report is one of a series of new reports from The Business Research Company that provides crohn's disease treatment market statistics, including crohn's disease treatment industry global market size, regional shares, competitors with a crohn's disease treatment market share, detailed crohn's disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the crohn's disease treatment industry. This crohn's disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The crohn's disease treatment market size has grown strongly in recent years. It will grow from $13.1 billion in 2025 to $13.99 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing crohn's disease prevalence, growing awareness of inflammatory bowel diseases, expansion of hospital pharmacy networks, availability of conventional anti-inflammatory drugs, improved diagnostic capabilities.
The crohn's disease treatment market size is expected to see strong growth in the next few years. It will grow to $18.86 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to pipeline expansion of biologics and small molecules, rising demand for personalized treatment, growth of online pharmacy penetration, increasing healthcare expenditure in emerging markets, long-term disease management focus. Major trends in the forecast period include rising adoption of biologic therapies, shift toward early and aggressive treatment approaches, increasing focus on steroid-sparing regimens, growth of oral small-molecule therapies, expansion of online and specialty pharmacy channels.
The growing prevalence of inflammatory bowel disorders is anticipated to drive the expansion of the Crohn's disease treatment market in the coming years. Inflammatory bowel disorders are a group of chronic conditions characterized by inflammation of the gastrointestinal tract and can affect any part of the digestive system, ranging from the mouth to the anus. Crohn's disease treatments work by reducing intestinal inflammation, helping to prevent symptom flare-ups and maintain disease remission. For example, in September 2023, according to the National Center for Biotechnology Information, a US-based government organization, the prevalence of Crohn's disease and ulcerative colitis has continued to rise, with inflammatory bowel disease projected at 825 cases per 100,000 people in 2023, including 410 cases of Crohn's disease and 414 cases of ulcerative colitis and IBD-unclassified. As a result, the increasing prevalence of these conditions is contributing to the growth of the Crohn's disease treatment market.
Leading companies operating in the Crohn's disease treatment market are focusing on the development and regulatory approval of innovative drugs, such as biosimilar ustekinumab, to deliver more effective and affordable treatment options, thereby improving patient outcomes and quality of life. Biosimilar ustekinumab is a biologic medicine that is highly similar to the reference drug ustekinumab, a monoclonal antibody used in the treatment of autoimmune diseases. For instance, in July 2024, Sandoz International GmbH launched Pyzchiva (ustekinumab) across Europe, making it the first ustekinumab biosimilar available in all dosage strengths, including a 130 mg vial specifically indicated for Crohn's disease. The product is approved for use in adults and children over six years of age with plaque psoriasis, psoriatic arthritis, and Crohn's disease, strengthening Sandoz's immunology portfolio while improving access to cost-effective therapies for chronic inflammatory conditions.
In June 2023, Merck acquired Prometheus Biosciences, Inc. for an undisclosed amount. Through this acquisition, Merck aims to reinforce its autoimmune disease pipeline by incorporating Prometheus' innovative therapies for Crohn's disease, ulcerative colitis, and other gastrointestinal disorders. Prometheus Biosciences, Inc. is a US-based company that develops and manufactures targeted treatments for Crohn's disease and related autoimmune conditions.
Major companies operating in the crohn's disease treatment market are AbbVie Inc., Janssen Pharmaceuticals, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Galapagos NV, Teva Pharmaceutical Industries Ltd., Mylan N.V., Glenmark Pharmaceuticals, Tillotts Pharma AG, Dr. Falk Pharma GmbH, Shire Pharmaceuticals, Salix Pharmaceuticals, Prometheus Laboratories Inc., Pfizer Inc., Novartis AG, Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd.
North America was the largest region in the global Crohn's disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crohn's disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the crohn's disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The Crohn's disease treatment market consists of sales of vedolizumab, methotrexate, and infliximab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Crohn's Disease Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses crohn's disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for crohn's disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The crohn's disease treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.